Cardiome Pharma Corporation (CRME)
Cardiome Pharma Corporation Key Statistics
Pro Data ExportCurrent Valuation
Dividends and Shares
| Dividend | |
| Dividend Yield | 0.00% * |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | |
| Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin | |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | -1480% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 15.31 |
| Debt to Equity Ratio | 0.9889 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -19.61% |
| Year to Date Stock Returns | -83.27% |
| 1 Year Stock Returns | -91.74% |
| 3 Year Stock Returns | -89.24% |
| 52 Week High | 5.84 |
| 52 Week Low | 0.3813 |
Income Statement
| Revenues TTM | 1.50M |
| Revenue Per Share TTM | 0.0245 |
| Revenue Growth | 33.33% |
| Gross Profit TTM | 1.50M |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | -27.92M |
| Earnings Per Share TTM | -0.47 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | -1.01M |
| Cash Financing TTM | 0.35M |
| Cash Operations TTM | -27.60M |
| Capital Expenditures | 0.00 * |
Share Statistics
| Shares Outstanding | 61.13M * |
Balance Sheet
| Cash and ST Investments | 48.64M |
| Total Assets | 54.03M |
| Liabilities | 28.30M |
| Book Value | 25.28M |
| Book Value per Share | 0.4135 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 0.00 * |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
Key stats for CRME are based on the quarter ending Dec. 31, 2011. Asterisk (*) indicates value is based on preliminary data. Preliminary key stats for CRME are based on the quarter ending March 31, 2012. When preliminary data is not available for all parts of a calculation, we use non-preliminary data for all parts of that calculation.
You may also be interested in these CRME related companies
CRME News
This company is amazing! A brick is more creative, eloquent and energetic than this $CRME management.
about 10 days ago by OysterX
about 10 days ago by OysterX
Very Interesting One : $CRME ( 0.70 ) This One Will Head Back Over a Buck ! Add On Your Watchlist And Keep An Eye On It ...
about 58 days ago by WallStreetBeats
about 58 days ago by WallStreetBeats
@PIER $CRME I have a feeling it may take a while. could test new lows, though the market hasn't helped.. but its a good buy here
about 60 days ago by peoples
about 60 days ago by peoples
$CRME With Merck calling it quits, is there a possibility that another big player might swoop in? Just wondering.
about 66 days ago by MarketBuy
about 66 days ago by MarketBuy
$CRME Long at .785. Let's go. Merck pullout just a minor setback. PPS is lower than book or cash per share! Easy long!
about 66 days ago by MarketBuy
about 66 days ago by MarketBuy
$CRME they have the cash on hand and it is equal or even more than share price.. its an easy buy
about 68 days ago by peoples
about 68 days ago by peoples
$CRME master at catching a falling knife... and it is not yet... but coming
about 70 days ago by peoples
about 70 days ago by peoples
$CRME I'll let you guys know when to buy.. it is starting to look interesting... sorry for those who thought they are getting in right
about 70 days ago by peoples
about 70 days ago by peoples
Oppenheimer Downgrades Cardiome Pharmaoration from Outperform to Perform, Removes PT from $ to $
Mar 19, 2:25PM Benzinga
Mar 19, 2:25PM Benzinga
$CRME Funny, this morning's plungle probably caused a few heart attacks. Ironic? A little.
about 70 days ago by MarketBuy
about 70 days ago by MarketBuy
Cardiome Announces Positive Phase 1 PK/PD Trial Results for Vernakalant Oral
Nov 03, 5:09PM GlobeNewswire
Nov 03, 5:09PM GlobeNewswire
Cardiome should benefit from significant vernakalant progress, says Oppenheimer
Sep 12, 7:28AM FlyOnTheWall
Sep 12, 7:28AM FlyOnTheWall
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CRME | 0.44 | +0.01 | +2.33% | 26.90M |
| CRMD | 0.27 | -0.01 | -3.50% | 3.081M |
| CRM | 147.00 | +0.79 | +0.54% | 20.14B |
| CRL | 33.56 | +0.21 | +0.63% | 1.641B |
| CPA | 83.85 | +0.62 | +0.74% | 3.713B |
| CP | 74.95 | -0.57 | -0.75% | 12.81B |
| COY | 7.40 | -0.04 | -0.54% | |
| COWN | 2.39 | +0.00 | +0.00% | |
| COVR | 1.54 | +0.00 | +0.00% | 39.42M |
| COV | 53.32 | -0.14 | -0.26% | 25.77B |
